natgillin/translations-raw huggingface dataset:
In addition, your doctor may consider giving you an additional dose of efavirenz to treat your HIV infection. 
Osim toga, liječnik će možda razmotriti i davanje dodatne doze efavirenza za liječenje Vaše infekcije HIV-om.
Uncommon: - dry mouth - incoherent speech - increased appetite - libido decreased - myalgia 
Manje često: - suha usta - inkoherentan govor - povećani apetit - smanjeni libido - mialgija
These immunosuppressants are not anticipated to impact exposure of efavirenz. 
Ne očekuje se da će ovi imunosupresivi utjecati na izloženost efavirenzu.
1 Anaemia was common and skin discolouration (increased pigmentation) was very common when emtricitabine was administered to paediatric patients. 
1 Anemija je bila česta, a promjena boje kože (povećana pigmentacija) vrlo česta kad se emtricitabin primjenjivao u pedijatrijskih bolesnika.
If you think you may have lactic acidosis, contact your doctor immediately. 
Mislite li da možda imate laktacidozu, odmah se obratite liječniku.
If bone abnormalities are suspected then appropriate consultation should be obtained. 
U slučaju sumnje na koštane abnormalnosti potrebno je odgovarajuće se konzultirati.
Some patients have had blood tests or symptoms indicating that their hepatitis has got worse after stopping emtricitabine or tenofovir disoproxil (two of the three components of Atripla). 
U nekih su bolesnika krvne pretrage ili simptomi ukazivali da se stanje hepatitisa pogoršalo nakon prestanka uzimanja emtricitabina ili tenofovirdizoproksila (dva od tri sastojka Atriple).
This medicine contains 23.6 mg sodium (main component of cooking/table salt) in each tablet. 
Ovaj lijek sadrži 23,6 mg natrija (glavni sastojak kuhinjske soli) u jednoj tableti.
Skin reactions 
Reakcije na koži
Because of interpatient variability in these parameters and concerns regarding development of resistance, HIV treatment guidelines should be consulted, also taking into consideration the reason for discontinuation. 
Zbog varijabilnosti ovih parametara među bolesnicima i mogućnosti razvoja rezistencije moraju se konzultirati smjernice za liječenje inficiranih HIV-om, a treba uzeti u obzir i razlog prekida terapije.
EU/1/07/430/001 30 film-coated tablets EU/1/07/430/002 90 (3 bottles of 30) film-coated tablets 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/07/430/001 30 filmom obloženih tableta EU/1/07/430/002 90 (3 boce po 30) filmom obloženih tableta
Cross-resistance profiles for efavirenz, nevirapine and delavirdine in vitro demonstrated that the K103N substitution confers loss of susceptibility to all three NNRTIs. 
Profili križne rezistencije za efavirenz, nevirapin i delavirdin in vitro pokazali su da supstitucija K103N dovodi do gubitka osjetljivosti na sva tri NNRTI lijeka.
If it is almost time (less than 12 hours) for your next dose anyway, do not take the missed dose. 
Ako je ionako skoro vrijeme da uzmete sljedeću dozu (preostalo je manje od 12 sati), nemojte uzeti propuštenu dozu.
However, in some patients, declines in creatinine clearance did not completely resolve despite tenofovir disoproxil discontinuation. 
Međutim, u nekih se bolesnika smanjenje klirensa kreatinina nije potpuno riješilo usprkos prekidu terapije tenofovirdizoproksila.
It is recommended that creatinine clearance is calculated in all patients prior to initiating therapy with Atripla and renal function (creatinine clearance and serum phosphate) is also monitored after two to four weeks of treatment, after three months of treatment and every three to six months thereafter in patients without renal risk factors. 
Preporučuje se izračunati klirens kreatinina u svih bolesnika prije nego se započne terapija Atriplom te pratiti funkciju bubrega (klirens kreatinina i razinu fosfata u serumu) nakon dva do četiri tjedna liječenja, nakon tri mjeseca liječenja i svakih tri do šest mjeseci nakon toga u bolesnika bez bubrežnih čimbenika rizika.
In such patients, interruption or discontinuation of treatment must be considered (see section 4.8). 
U tih bolesnika mora se razmotriti privremeni ili trajni prekid terapije (vidjeti dio 4.8).
One patient experienced involuntary muscle contractions. 
Kod jednog je bolesnika došlo do nekontrolirane kontrakcije mišića.
If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment. 
Ako uočite bilo koje simptome infekcije ili druge simptome poput slabosti mišića, slabosti koja počinje u šakama i stopalima i pomiče se nagore prema trupu tijela, osjećaja lupanja srca, nevoljnog drhtanja ili hiperaktivnosti, odmah obavijestite svog liječnika kako biste dobili potrebno liječenje.
Efavirenz may also cause impaired concentration and/or somnolence. 
Efavirenz može uzrokovati i pad koncentracije i/ili somnolenciju.
In virologically suppressed patients, the clinical relevance of this reduction can be expected to be limited (see section 5.1). 
U bolesnika s virološkom supresijom može se očekivati ograničen klinički značaj ovog smanjenja (vidjeti dio 5.1).
The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3'-sulphoxide diastereomers (approximately 9% of dose) and conjugation with glucuronic acid to form 2'-O-glucuronide (approximately 4% of dose). 
Biotransformacija emtricitabina uključuje oksidaciju tiolne skupine, pri čemu nastaju diastereomeri 3'-sulfoksida (približno 9% doze) i konjugaciju s glukoronskom kiselinom, pri čemu nastaje 2'-O-glukoronid (približno 4% doze).
The clinical outcome of this observed reduction of boceprevir trough concentrations has not been directly assessed. 
Klinički ishod ovog opaženog smanjenja najniže koncentracije boceprevira nije izravno procijenjen.
Since no dose recommendation can be made for itraconazole when used with Atripla, an alternative antifungal treatment should be considered. 
Budući da se ne može dati preporuka doze za itrakonazol kada se primjenjuje s Atriplom, treba razmotriti alternativnu antifungalnu terapiju.
In uninfected volunteers, multiple doses of 200 to 400 mg per day for 10 days resulted in a lower than predicted extent of accumulation (22 to 42% lower) and a shorter terminal half-life of 40 to 55 hours (single dose half-life 52 to 76 hours). 
U neinficiranih dobrovoljaca više doza od 200 do 400 mg po danu tijekom 10 dana rezultiralo je manjom akumulacijom lijeka od predviđenog (manja za 22 do 42%) i kraćim poluvijekom od 40 do 55 sati (poluvijek jedne doze 52 do 76 sati).
In particular, severe depression was more common in those with a history of depression. 
Posebno je uočena češća teška depresija u osoba s depresijom u anamnezi.
The silica gel desiccant is contained in a separate sachet and should not be swallowed. 
Sredstvo za sušenje od silikagela nalazi se u zasebnoj vrećici i ne smije se progutati.
Stayed on original treatment regimen (N=97) n/N (%) 
Ostali na prvotnom režimu liječenja (N=97) n/N (%)
Pharmacotherapeutic group: Antiviral for systemic use, antivirals for treatment of HIV infections, combinations, ATC code: J05AR06 
Farmakoterapijska skupina: Antivirusni lijek za sistemsku primjenu, antivirusni lijekovi za liječenje infekcije HIV-om, kombinacije, ATK oznaka: J05AR06
In other studies (prospective and cross-sectional), the most pronounced decreases in BMD were seen in patients treated with tenofovir disoproxil as part of a regimen containing a boosted protease inhibitor. 
U drugim ispitivanjima (prospektivnim i presječnim), najizraženija smanjenja BMD-a bila su opažena u bolesnika liječenih tenofovirdizoproksilom u sklopu režima koji je sadržavao pojačan inhibitor proteaze.
• forgetfulness, confusion, fitting (seizures), incoherent speech, tremor (shaking) 
• zaboravljivost, zbunjenost, grčenje (epileptični napadaji), nekoherentan govor, tremor (drhtanje)
Patients coinfected with HIV and HBV 
Bolesnici istodobno inficirani HIV-om i HBV-om
Carbamazepine plasma levels should be monitored periodically. 
Periodički treba kontrolirati razine karbamazepina u plazmi.
Pharmacokinetic studies have not been performed with efavirenz, emtricitabine or tenofovir in elderly patients (over 65 years of age). 
Nisu provedena farmakokinetička ispitivanja efavirenza, emtricitabina ili tenofovira u starijih bolesnika (starijih od 65 godina).
Since efavirenz is highly protein bound, dialysis is unlikely to remove significant quantities of it from blood. 
Budući da efavirenz ima svojstvo snažnog vezivanja na proteine, nije vjerojatno da se dijalizom mogu ukloniti značajne količine efavirenza iz krvi.
Because of the long half-life of efavirenz, use of adequate contraceptive measures for 12 weeks after discontinuation of Atripla is recommended. 
Zbog dugog poluvremena efavirenza preporučuje se korištenje odgovarajućih metoda kontracepcije 12 tjedana nakon prekida terapije Atriplom.
Reproductive toxicity studies showed increased foetal resorptions in rats. 
Ispitivanja reproduktivne toksičnosti pokazala su povećanu resorpciju zametaka u štakora.
In some cases, your doctor may need to adjust your dose or check your blood levels. 
U nekim slučajevima liječnik treba prilagoditi dozu lijeka ili provjeriti njegovu razinu u krvi.
• difficulty sleeping, abnormal dreams, difficulty concentrating, drowsiness 
• otežano spavanje, abnormalni snovi, poteškoće u koncentraciji, omamljenost
Both the K65R and M184V/I mutation remain fully susceptible to efavirenz. 
Mutacije K65R i M184V/I potpuno su osjetljive na efavirenz.
Data are available from 286 patients who switched to Atripla: 160 had previously received efavirenz, emtricitabine and tenofovir disoproxil, and 126 had previously received Combivir and efavirenz. 
Dostupni su podaci za 286 bolesnika koji su prebačeni na liječenje Atriplom: 160 njih prethodno je primalo efavirenz, emtricitabin i tenofovirdizoproksil, a 126 je prethodno primalo Combivir i efavirenz.
- if you have a heart disorder, such as abnormal electrical signal called prolongation of the QT interval. 
- ako imate srčani poremećaj, kao što je abnormalan električni signal koji se naziva produljenje QT intervala.
Tenofovir is primarily excreted by the kidneys by both filtration and an active tubular transport system with approximately 70 to 80% of the dose excreted unchanged in urine following intravenous administration. 
Tenofovir se prvenstveno izlučuje preko bubrega filtracijom i aktivnim tubularnim transportnim sustavom, pri čemu se oko 70-80% doze izlučuje u nepromijenjenom obliku u mokraći nakon intravenske primjene.
The use of Atripla in children and adolescents has not been studied. 
Primjena Atriple u djece i adolescenata nije ispitana.
When efavirenz is co-administered with a calcium channel blocker that is a substrate of the CYP3A4 enzyme, there is a potential for reduction in the plasma concentrations of the calcium channel blocker. 
Ako se efavirenz primjenjuje istodobno s blokatorom kalcijevih kanala koji je supstrat enzima CYP3A4, postoji mogućnost smanjenja plazmatske koncentracije blokatora kalcijevih kanala.
A positive relationship between efavirenz concentration and QTc prolongation was observed. 
Opažen je pozitivan odnos između koncentracije efavirenza i produljenja QTc-a.
Rosuvastatin is largely excreted unchanged via the faeces, therefore interaction with efavirenz is not expected. 
Rosuvastatin se uglavnom izlučuje putem stolice i zato se ne očekuje interakcija s efavirenzom.
Patients receiving Atripla or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases. 
U bolesnika koji primaju Atriplu ili neku drugu antiretrovirusnu terapiju mogu se i dalje razvijati oportunističke infekcije i druge komplikacije infekcije HIV-om, pa bi zbog toga trebali ostati pod strogim kliničkim nadzorom liječnika koji imaju iskustva u liječenju bolesnika s bolestima povezanim s HIV-om.
If there is evidence of worsening liver disease or persistent elevations of serum transaminases to greater than 5 times the upper limit of the normal range, the benefit of continued therapy with Atripla needs to be weighed against the potential risks of significant liver toxicity. 
Postoje li dokazi o pogoršanju bolesti jetre ili stalno povišenje serumskih transaminaza za više od 5 puta iznad gornje granice normalnog raspona, nužno je procijeniti koristi nastavka terapije Atriplom naprema mogućim rizicima značajne toksičnosti za jetru.
In vitro binding of emtricitabine to human plasma proteins is < 4% and independent of concentrations over the range of 0.02 to 200 µg/ml. 
In vitro vezivanje emtricitabina na proteine ljudske plazme je < 4% i neovisno je o koncentracijama u rasponu od 0,02 do 200 µg/ml.
- Bupropion, a medicine used to treat depression or to help you stop smoking, as your doctor may need to change your dose of bupropion. 
- Bupropion, lijek koji se koristi za liječenje depresije ili kao pomoć za prestanak pušenja: liječnik će Vam možda morati promijeniti dozu bupropiona.
All 3 subjects had received a fixed dose combination of lamivudine and zidovudine (Combivir) and efavirenz for 144 weeks and then switched to Atripla. 
Sva 3 ispitanika primala su fiksnu dozu kombinacije lamivudina i zidovudina (Combivir) i efavirenz 144 tjedana, a potom su bili prebačeni na Atriplu.
Studies conducted with other medicinal products 
Ispitivanja provedena s drugim lijekovima
Following oral administration, the elimination half-life of emtricitabine is approximately 10 hours. 
Nakon peroralne primjene, poluvrijeme eliminacije emtricitabina je približno 10 sati.
• itchy rash to the skin caused by a reaction to sunlight 
• osip na koži koji svrbi uzrokovan reakcijom na sunce
The safety and efficacy of Atripla have not been studied for the treatment of chronic HBV infection. 
Nije provedeno ispitivanje sigurnosti i djelotvornosti primjene Atriple u liječenju kronične infekcije virusom HBV-a.
Confirmatory testing by a more specific method such as gas chromatography/mass spectrometry is recommended in such cases. 
U takvim se slučajevima preporučuje potvrditi pozitivan rezultat specifičnijom metodom kao što je plinska kromatografija/masena spektrometrija.
Modified LOCF: Post-hoc analysis where patients who failed virologically or discontinued for adverse events were treated as failures; for other drop-outs, the LOCF (last observation carried forward) method was applied 
Prilagođeni LOCF: Post-hoc analiza u kojoj su bolesnici u kojih je došlo do virološkog neuspjeha ili su prestali s liječenjem zbog nuspojava tretirani kao neuspješni; na ostale isključene bolesnike primijenjena je metoda LOCF (engl. last observation carried forward)
Sufficient data on the tolerability of efavirenz with low-dose ritonavir (100 mg, once or twice daily) are not available. 
Nije dostupno dovoljno podataka o toleranciji efavirenza u kombinaciji s niskom dozom ritonavira (100 mg, jednom ili dva puta dnevno).
Patients with mild liver disease (Child-Pugh-Turcotte (CPT), Class A) may be treated with the normal recommended dose of Atripla (see sections 4.3, 4.4 and 5.2). 
Bolesnici s blagom bolešću jetre (Child-Pugh-Turcotte (CPT), stadij A) mogu se liječiti uobičajenom preporučenom dozom Atriple (vidjeti dio 4.3, 4.4 i 5.2).
Despite the decrease in buprenorphine exposure, no patients exhibited withdrawal symptoms. 
Unatoč smanjenju izloženosti buprenorfinu, nijedan bolesnik nije pokazao simptome apstinencijske krize.
Patients should be advised that if they experience symptoms such as severe depression, psychosis or suicidal ideation, they should contact their doctor immediately to assess the possibility that the symptoms may be related to the use of efavirenz, and if so, to determine whether the risk of continued therapy outweighs the benefits (see section 4.8). 
Bolesnike treba uputiti da se, osjete li simptome poput teške depresije, psihoze ili samoubilačkih ideja, moraju odmah obratiti svojem liječniku radi procjene moguće povezanosti tih simptoma s upotrebom efavirenza te, ako je tako, radi utvrđivanja nadmašuje li rizik uslijed nastavka terapije koristi od terapije (vidjeti dio 4.8).
Efavirenz concentrations not measured, no effect is expected. 
Koncentracije efavirenza nisu mjerene, ne očekuje se nikakav učinak.
Carcinogenicity studies in male mice, male and female rats were negative. 
Istraživanja kancerogenosti u muških miševa te muških i ženskih štakora bila su negativna.
Experience with efavirenz in patients who discontinued other antiretroviral agents of the NNRTI class is limited. 
Iskustva s efavirenzom u bolesnika koji su prekinuli uzimanje drugih antiretrovirusnih lijekova klase NNRTI ograničena su.
Talk to your doctor or pharmacist before taking Atripla. 
Obratite se svom liječniku ili ljekarniku prije nego uzmete Atriplu.
If overdose occurs, the patient must be monitored for evidence of toxicity (see section 4.8), and standard supportive treatment applied as necessary. 
U slučaju predoziranja bolesnik mora biti pod nadzorom zbog znakova toksičnosti (vidjeti dio 4.8) te mu se, prema potrebi, mora pružiti standardno potporno liječenje.
These side effects may start in the first 1 or 2 days of treatment and usually go away after the first 2 to 4 weeks. 
Te nuspojave mogu se pojaviti u prvih 1 ili 2 dana liječenja, a obično nestaju nakon prva 2 do 4 tjedna.
In clinical controlled studies of efavirenz, nervous system symptoms of moderate to severe intensity were experienced by 19% (severe 2%) of patients, and 2% of patients discontinued therapy due to such symptoms. 
U klinički kontroliranim ispitivanjima efavirenza simptomi živčanog sustava umjerenog do teškog intenziteta uočeni su u 19% (teški oblik 2%) bolesnika, a u 2% bolesnika terapija je zbog tih simptoma prekinuta.
Patients should be informed that if they do occur, these common symptoms are likely to improve with continued therapy and are not predictive of subsequent onset of any of the less frequent psychiatric symptoms. 
Bolesnicima treba objasniti da će se, ukoliko se pojave, ti česti simptomi vjerojatno ublažiti tijekom trajanja terapije te da se na temelju njih ne može predvidjeti naknadna pojava bilo kakvih manje čestih psihijatrijskih simptoma.
Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to CART. 
Iako se smatra da je etiologija multifaktorska (uključujući primjenu kortikosteroida, konzumaciju alkohola, tešku imunosupresiju, veći indeks tjelesne mase), zabilježeni su slučajevi osteonekroze osobito u bolesnika s uznapredovalom HIV-bolešću i/ili dugotrajnom izloženošću CART-u.
Immune system disorders: Common allergic reaction 
Poremećaji imunološkog sustava: Često alergijske reakcije
Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). 
U nekih se bolesnika koji uzimaju kombiniranu antiretrovirusnu terapiju može razviti koštana bolest koja se naziva osteonekrozom (odumiranje koštanog tkiva uzrokovano prestankom opskrbe kosti krvlju).
Also, emtricitabine did not inhibit uridine 5'-diphosphoglucuronyl transferase, the enzyme responsible for glucuronidation. 
Isto tako, ni emtricitabin nije inhibirao uridin-5'-difosfoglukoriniltransferazu, enzim odgovoran za glukuronidaciju.
These are listed under Do not take Atripla, at the start of section 2. 
Ti su lijekovi navedeni pod Nemojte uzimati Atriplu na početku dijela 2.
Women should not get pregnant during treatment with Atripla and for 12 weeks thereafter. 
Žene ne bi smjele zatrudnjeti tijekom liječenja Atriplom niti 12 tjedana nakon prekida liječenja.
This may make some side effects (for example, dizziness, drowsiness) less troublesome. 
To može smanjiti negativan utjecaj nekih nuspojava (na primjer, omaglice, omamljenosti).
Voxilaprevir:↓ 
Očekivano: voxilaprevir:↓
These patients should be carefully monitored for efavirenz adverse reactions, especially nervous system symptoms. 
Te bolesnike potrebno je pomno pratiti radi pojave nuspojava efavirenza, naročito simptoma na živčanom sustavu.
Tenofovir concentrations not measured, no effect is expected. 
Koncentracije tenofovira nisu mjerene, ne očekuje se nikakav učinak.
Co-administration of atazanavir/ritonavir with tenofovir resulted in increased exposure to tenofovir. 
Istodobna primjena atazanavira/ritonavira s tenofovirom dovela je do povećane izloženosti tenofoviru.
Compounds or herbal preparations (for example Ginkgo biloba extracts and St. John's wort) which induce these enzymes may give rise to decreased plasma concentrations of efavirenz. 
Spojevi ili biljni pripravci (na primjer, ekstrakt Ginkgo bilobe i gospina trava), koji induciraju ove enzime, mogu dovesti do smanjenja koncentracije efavirenza u plazmi.
Efavirenz plasma exposure may be increased in patients with homozygous G516T genetic variant of the CYP2B6 isozyme. 
Plazmatska izloženost efavirenzu može biti povećana kod bolesnika s homozigotskom genskom inačicom G516T izozima CYP2B6.
Metabolism and nutrition disorders: Very common hypophosphataemia2 
Poremećaji metabolizma i prehrane: Vrlo često hipofosfatemija2
You do not need to take another tablet if you were sick more than 1 hour after taking Atripla. 
Drugu tabletu ne trebate uzimati ako ste povraćali nakon što je prošlo više od 1 sat nakon uzimanja Atriple.
Therapy should be initiated by a physician experienced in the management of HIV infection. 
Terapiju mora započeti liječnik s iskustvom u liječenju infekcije HIV-om.
Since decreased concentrations of artemether, dihydroartemisinin, or lumefantrine may result in a decrease of antimalarial efficacy, caution is recommended when Atripla and artemether/lumefantrine tablets are co-administered. 
Budući da smanjene koncentracije artemetera, dihidroartemisinina ili lumefantrina mogu imati za posljedicu smanjenu antimalarijsku djelotvornost, preporučuje se oprez pri istodobnoj primjeni Atriple i artemeter/lumefantrin tableta.
They include some common medicines and some herbal preparations (including St. John's wort) which can cause serious interactions. 
Među njima su neki lijekovi koji se često uzimaju i neki biljni pripravci (uključujući gospinu travu) koji mogu uzrokovati ozbiljne interakcije.
Signs of osteonecrosis are joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement. 
Znakovi osteonekroze su ukočenost zglobova, bolovi (osobito u kuku, koljenu i ramenu) te otežano gibanje.
Efavirenz, one of the active components of Atripla, may remain in your blood for a time after therapy is stopped. 
Efavirenz, jedna od djelatnih tvari lijeka Atriple, može se zadržati u krvi određeno vrijeme nakon prekida liječenja.
The biliary hyperplasia regressed upon cessation of dosing. 
Bilijarna hiperplazija povukla se nakon prestanka davanja doza.
The bone toxicity in young adult rats and dogs occurred at exposures ≥ 5-fold the exposure in paediatric or adult patients; bone toxicity occurred in juvenile infected monkeys at very high exposures following subcutaneous dosing (≥ 40-fold the exposure in patients). 
U mladih odraslih štakora i pasa toksičnost za kosti pokazala se pri izloženosti dozi ≥ 5 puta većoj od izloženosti kod pedijatrijskih ili odraslih bolesnika; toksičnost za kosti pojavila se u mladih zaraženih majmuna pri vrlo visokim izloženostima nakon supkutanog doziranja (≥ 40 puta veća izloženost nego u bolesnika).
Efavirenz may be an inducer of CYP2C19 and CYP2C9; however, inhibition has also been observed in vitro and the net effect of co-administration with substrates of these enzymes is not clear (see section 5.2). 
Efavirenz može biti induktor CYP2C19 i CYP2C9; međutim in vitro je opažena i inhibicija pa neto učinak istodobne primjene sa supstratima ovih enzima nije jasan (vidjeti dio 5.2).
Darunavir/ritonavir should be used with caution in combination with Atripla. 
Darunavir/ritonavir trebaju se uzimati pažljivo u kombinaciji s Atriplom.